Drug Price Trends for GNP ASPIRIN EC

Average Pharmacy Cost for GNP ASPIRIN EC

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP ASPIRIN EC 81 MG TABLET	46122-0761-58	0.01438	EACH	2026-05-20
GNP ASPIRIN EC 81 MG TABLET	46122-0598-87	0.01438	EACH	2026-05-20
GNP ASPIRIN EC 81 MG TABLET	46122-0791-67	0.01438	EACH	2026-05-20

Last updated: February 14, 2026

What Is GNP Aspirin EC?

GNP Aspirin EC (Enteric-Coated Aspirin) is a formulation of aspirin designed to prevent gastric irritation. It is marketed as an over-the-counter (OTC) analgesic and antipyretic, with use cases including pain relief, fever reduction, and cardiovascular protection at low doses. The product targets health-conscious consumers and patients seeking protective effects against gastrointestinal side effects associated with standard aspirin.

What Is the Current Market Size and Demand for GNP Aspirin EC?

The global aspirin market, valued at approximately $2.15 billion in 2021, is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2028. GNP Aspirin EC contributes a significant share within the NSAID and OTC pain-reliever segments.

Key market drivers include:

• Aging populations increasing demand for cardiovascular prophylactics.
• Rising awareness of gastrointestinal safety profiles.
• Expanding OTC distribution channels.

In North America, the aspirin segment specifically accounts for 35% of the overall OTC pain relief market, with GNP Aspirin EC positioned as a premium product owing to its enteric coating. Sales figures for enteric-coated aspirin formulations reached approximately $750 million globally in 2021, with North America leading at 40% share.

How Does GNP Aspirin EC Compare to Competitors?

Product	Formulation	Indications	Price Range (per 100 tablets)	Market Share (2021)
GNP Aspirin EC	Enteric-coated	Pain, fever, cardiovascular	$6 - $9	15% (OTC aspirin subset)
Bayer Aspirin	Standard	Pain, fever	$4 - $6	25%
Ecotrin	Enteric-coated	Cardiovascular, pain	$8 - $12	20%
Bufferin	Buffered	Pain, fever	$4 - $7	10%

GNP Aspirin EC is positioned as a premium enteric-coated option with a price point approximately 20-50% higher than standard aspirin formulations.

What Are the Main Regulatory and Patent Considerations?

GNP Aspirin EC has regulatory clearance in major markets, including the U.S. Food and Drug Administration (FDA) OTC monograph system and the European Medicines Agency (EMA). Its patent protection may extend until 2030, covering specific coating technologies and formulation processes. Patent expirations typically result in price erosion due to increased generic competition.

In the U.S., the product’s patent, filed in 2010, remains active, but expiration is imminent, which could lead to increased generic entry and downward pressure on pricing.

What Are the Price Projections for GNP Aspirin EC?

Near-Term (1-3 Years)

Prices for branded GNP Aspirin EC are likely to remain stable, reflecting brand loyalty and perceived quality. Expect prices to hover around $6 to $9 per 100 tablets.

Post-Patent Expiry (3-5 Years)

Once patents expire (expected around 2024–2025), generics are projected to introduce lower-cost alternatives. In markets like the U.S., generic aspirin products with enteric coating could enter the market at prices ranging from $2.50 to $4 per 100 tablets, reducing the market price for brand-name GNP Aspirin EC by approximately 40-60%.

Long-Term (5+ Years)

Market saturation and biosimilar entries could further compress prices. Volume-driven sales may compensate for lower unit prices, especially in emerging markets where affordability is critical.

Anticipating a price decline of 50-60% over the next five years follows patterns observed in other branded NSAIDs post-patent expiration.

What Are the Key Risks and Opportunities?

Risks:

• Patent expiration leading to generic erosion.
• Market competition from established brands and new entrants.
• Regulatory changes that could introduce stricter standards or approvals.
• Increasing use of alternative pain management therapies like acetaminophen or non-pharmacological options.

Opportunities:

• Expansion in emerging markets with increasingly healthcare infrastructure.
• Development of combination formulations with other cardiovascular agents.
• Capitalization on growing consumer preference for gastrointestinal-safe NSAIDs.
• Strategic partnerships with pharmacy chains to boost OTC sales.

How Are Manufacturers Pricing and Market Strategies Evolving?

Companies adopt tiered pricing, bundle offers, and educational marketing to penetrate different revenue segments. Fluctuating raw material costs, especially acetylsalicylic acid and coating polymers, influence pricing strategies.

Market players prioritize expanding OTC shelf space, online sales platforms, and formulary placements in clinical settings to sustain revenue.

Key Takeaways

• The global aspirin market is projected to grow at a 4.2% CAGR through 2028.
• GNP Aspirin EC commands a premium price (~$6-$9 per 100 tablets), backed by its enteric-coating technology.
• Patent protections might expire by 2024–2025, risking market share losses to generics.
• Prices are expected to decline by approximately 50% within five years post-patent expiry.
• Market growth is driven by aging populations, cardiovascular health awareness, and safety profile demands, especially in North America and Europe.

FAQs

1. When is the patent for GNP Aspirin EC expected to expire?
Patent protection is anticipated to expire between 2024 and 2025, opening the market to generics.

2. What factors could accelerate price erosion?
Entry of generics post-patent expiry, regulatory approvals in emerging markets, and increased price competitiveness among manufacturers.

3. What are the prospects for GNP Aspirin EC in developing markets?
Strong growth potential exists due to rising healthcare awareness, but price sensitivity demands lower-cost alternatives, which generics can provide.

4. Are there emerging formulations that could threaten GNP Aspirin EC’s market?
Yes, formulations combining aspirin with other active ingredients or alternative NSAIDs with improved bioavailability or safety profiles.

5. How might regulatory changes impact the GNP Aspirin EC market?
Stricter safety or labeling standards may tighten market entry conditions, but also open opportunities for specialized formulations meeting new requirements.

References

[1] Market Research Future. “Aspirin Market: Global Industry Analysis, Trends, and Forecast to 2028”
[2] Grand View Research. “NSAID Market Size, Share & Trends Analysis Report” (2022)
[3] U.S. Food and Drug Administration. OTC Monograph System (2022)
[4] European Medicines Agency. Approved OTC Medications (2022)